Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
01:27pm, Tuesday, 28'th Apr 2026
Amneal leans on generics stability, biosimilar launches, and Crexont growth as 2026 guidance points to higher EBITDA and EPS despite Specialty headwinds.
AMRX Valuation: What 1.69x Sales Means for Investors
01:27pm, Tuesday, 28'th Apr 2026
Amneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
10:46am, Monday, 27'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
10:33am, Thursday, 23'rd Apr 2026
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 23'rd Apr 2026
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
03:30pm, Wednesday, 22'nd Apr 2026
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
08:21am, Wednesday, 22'nd Apr 2026
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.21 per share a year ago.
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
06:46am, Wednesday, 22'nd Apr 2026
Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion that will expand the drugmaker's biosimilars business.
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
06:17am, Wednesday, 22'nd Apr 2026
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Cont
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
04:59pm, Tuesday, 21'st Apr 2026
Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positiv
A Look at Amneal Pharmaceuticals Inc (AMRX) After 4.7% Decline -- GF Value $6.98 vs Price $13.26
05:56pm, Monday, 20'th Apr 2026
On April 20, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 4.7%, bringing the current price to $13.26. The stock has traded within a 52-week range of $7.0
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” t
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
11:39am, Friday, 17'th Apr 2026
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it sees as an attractive entry point following a
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
07:36am, Friday, 17'th Apr 2026
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it...
